Dissolution therapy for the treatment of gallstones
- David Nunes, MD, FRCPI
David Nunes, MD, FRCPI
- Associate Professor of Medicine
- Boston University
- Section Editor
- Sanjiv Chopra, MD, MACP
Sanjiv Chopra, MD, MACP
- Editor-in-Chief — Gastroenterology/Hepatology
- Section Editor — General Hepatology; Gallbladder and Biliary Tract Disease
- Professor of Medicine
- Harvard Medical School
- Senior Consultant in Hepatology
- James Tullis Firm Chief
- Beth Israel Deaconess Medical Center
The role for the medical management of gallstone disease has decreased since the introduction of laparoscopic cholecystectomy. Cholecystectomy remains the preferred method because of its reduced cost, definitive nature, safety, and increased convenience for the patient [1,2]. Furthermore, medical therapy of gallstones has been hampered by the high incidence of recurrent stones. As a result, interest in nonsurgical techniques for the management of gallstones has waned significantly.
Nevertheless, medical management using dissolution therapy may be an alternative to cholecystectomy in selected patients with symptomatic gallstone disease with a view either to eliminating stones or reducing the risk of further complications. In the past, the nonsurgical treatment of gallstones also included extracorporeal shock wave lithotripsy, though this is now rarely done. Successful treatment depends upon a functioning gallbladder and varies based upon the number, size, and composition of the stone(s). As a result, many symptomatic patients have stones that are not ideally suited to dissolution therapy, producing less than optimal results. The primary candidates for elective nonsurgical management of gallstones are patients who are symptomatic or are at high risk for developing symptomatic gallstone disease, but are not candidates for surgery. (See "Patient selection for the nonsurgical treatment of gallstone disease".)
Patients with acute gallstone-related disease who are not surgical candidates may require percutaneous cholecystostomy. Case series have also described placement of a cystic duct stent during endoscopic retrograde cholangiopancreatography in patients with gallstone-related disease (such as biliary colic, acute cholecystitis, acalculous cholecystitis, and gallstone pancreatitis) and serious comorbidities that precluded other approaches [3-8]. Although placement of such stents may be technically challenging, they can provide sufficient palliation until more definitive therapy can be performed. (See "Acalculous cholecystitis" and "Treatment of acute calculous cholecystitis".)
This topic will review dissolution therapy for the elective treatment of gallstones. Endoscopic sphincterotomy for gallstone-related disease without subsequent cholecystectomy, the selection of patients for nonsurgical treatment of gallstones, and laparoscopic cholecystectomy are discussed separately. (See "Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy" and "Patient selection for the nonsurgical treatment of gallstone disease" and "Laparoscopic cholecystectomy".)
COMPOSITION OF GALLSTONES
Most medical therapies have been developed for the management of cholesterol-rich gallstones. Gallstones are composed of a mixture of cholesterol, calcium bilirubinate, proteins, and mucin. They are broadly classified as cholesterol, black pigment, or brown pigment stones, depending upon the predominant constituents, although most "cholesterol" stones have a mixed composition with small amounts of calcium and bilirubin salts. Black pigment stones result from hemolysis and consist primarily of calcium bilirubinate. Brown pigment stones are associated with bacterial and helminthic infection of the biliary system and are often found in the bile ducts in association with prior biliary manipulation or in association with biliary infestation. They may also occur as de novo common bile duct stones following cholecystectomy.
- Darzi A, Geraghty JG, Williams NN, et al. The pros and cons of laparoscopic cholecystectomy and extracorporeal shock wave lithotripsy in the management of gallstone disease. Ann R Coll Surg Engl 1994; 76:42.
- Portincasa P, van de Meeberg P, van Erpecum KJ, et al. An update on the pathogenesis and treatment of cholesterol gallstones. Scand J Gastroenterol Suppl 1997; 223:60.
- Conway JD, Russo MW, Shrestha R. Endoscopic stent insertion into the gallbladder for symptomatic gallbladder disease in patients with end-stage liver disease. Gastrointest Endosc 2005; 61:32.
- Shrestha R, Trouillot TE, Everson GT. Endoscopic stenting of the gallbladder for symptomatic gallbladder disease in patients with end-stage liver disease awaiting orthotopic liver transplantation. Liver Transpl Surg 1999; 5:275.
- Shrestha R, Bilir BM, Everson GT, Steinberg SE. Endoscopic stenting of gallbladder for symptomatic cholelithiasis in patients with end-stage liver disease awaiting orthotopic liver transplantation. Am J Gastroenterol 1996; 91:595.
- Gaglio PJ, Buniak B, Leevy CB. Primary endoscopic retrograde cholecystoendoprosthesis: a nonsurgical modality for symptomatic cholelithiasis in cirrhotic patients. Gastrointest Endosc 1996; 44:339.
- Kalloo AN, Thuluvath PJ, Pasricha PJ. Treatment of high-risk patients with symptomatic cholelithiasis by endoscopic gallbladder stenting. Gastrointest Endosc 1994; 40:608.
- Schlenker C, Trotter JF, Shah RJ, et al. Endoscopic gallbladder stent placement for treatment of symptomatic cholelithiasis in patients with end-stage liver disease. Am J Gastroenterol 2006; 101:278.
- Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am 1991; 20:1.
- Attili AF, Carulli N, Roda E, et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.). Am J Epidemiol 1995; 141:158.
- Attili AF, Capocaccia R, Carulli N, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology 1997; 26:809.
- Sherlock S, Dooley J. Diseases of the liver and biliary system, Blackwell Science, Oxford 2002.
- Trotman BW, Soloway RD. Pigment vs cholesterol cholelithiasis: clinical and epidemiological aspects. Am J Dig Dis 1975; 20:735.
- Fromm H, Malavolti M. Bile acid dissolution therapy of gallbladder stones. Baillieres Clin Gastroenterol 1992; 6:689.
- Peine CJ. Gallstone-dissolving agents. Gastroenterol Clin North Am 1992; 21:715.
- Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994; 121:207.
- Guarino MP, Cong P, Cicala M, et al. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 2007; 56:815.
- Hardison WG, Grundy SM. Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology 1984; 87:130.
- Uchida K, Akiyoshi T, Igimi H, et al. Differential effects of ursodeoxycholic acid and ursocholic acid on the formation of biliary cholesterol crystals in mice. Lipids 1991; 26:526.
- Wang DQ, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol 2003; 285:G494.
- van de Heijning BJ, van de Meeberg PC, Portincasa P, et al. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Dig Dis Sci 1999; 44:190.
- Tomida S, Abei M, Yamaguchi T, et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 1999; 30:6.
- Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl 1994; 204:27.
- Tangedahl T, Carey WD, Ferguson DR, et al. Drug and treatment efficacy of chenodeoxycholic acid in 97 patients with cholelithiasis and increased surgical risk. Dig Dis Sci 1983; 28:545.
- Maton PN, Iser JH, Reuben A, et al. Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Factors influencing efficacy, withdrawal, symptoms and side effects and post-dissolution recurrence. Medicine (Baltimore) 1982; 61:86.
- Tint GS, Salen G, Colalillo A, et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 1982; 97:351.
- Tudyka J, Kratzer W, Janowitz P, et al. Combined bile acid therapy is more effective on biliary lipids and dissolution rates than monotherapy after gallstone lithotripsy. Am J Gastroenterol 1995; 90:1942.
- May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials. Aliment Pharmacol Ther 1993; 7:139.
- Jazrawi RP, Pigozzi MG, Galatola G, et al. Optimum bile acid treatment for rapid gall stone dissolution. Gut 1992; 33:381.
- Petroni ML, Jazrawi RP, Pazzi P, et al. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group. Aliment Pharmacol Ther 2001; 15:123.
- Di Ciaula A, Wang DQ, Wang HH, et al. Targets for current pharmacologic therapy in cholesterol gallstone disease. Gastroenterol Clin North Am 2010; 39:245.
- Kupfer RM, Maudgal DP, Northfield TC. Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet. Dig Dis Sci 1982; 27:1025.
- Lanzini A, Facchinetti D, Northfield TC. Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration. Gastroenterology 1988; 95:1029.
- Senior JR, Johnson MF, DeTurck DM, et al. In vivo kinetics of radiolucent gallstone dissolution by oral dihydroxy bile acids. Gastroenterology 1990; 99:243.
- Bazzoli F, Festi D, Mazzella G, et al. Acquired gallstone opacification during cholelitholytic treatment with chenodeoxyholic, ursodeoxycholic, and tauroursodeoxycholic acids. Am J Gastroenterol 1995; 90:978.
- Bateson MC, Bouchier IA, Trash DB, et al. Calcification of radiolucent gall stone during treatment with ursodeoxycholic acid. Br Med J (Clin Res Ed) 1981; 283:645.
- Walters JR, Hood KA, Gleeson D, et al. Combination therapy with oral ursodeoxycholic and chenodeoxycholic acids: pretreatment computed tomography of the gall bladder improves gall stone dissolution efficacy. Gut 1992; 33:375.
- Pereira SP, Veysey MJ, Kennedy C, et al. Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse. Dig Dis Sci 1997; 42:1775.
- Frigerio G. Ursodeoxycholic acid in the treatment of dyspepsia; Report of a multicenter controlled trial. Curr Ther Res 1979; 26:214.
- Venneman NG, Besselink MG, Keulemans YC, et al. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology 2006; 43:1276.
- Petroni ML, Jazrawi RP, Pazzi P, et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 2000; 12:695.
- Portincasa P, van Erpecum KJ, van De Meeberg PC, et al. Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Hepatology 1996; 24:580.
- Lanzini A, Jazrawi RP, Kupfer RM, et al. Gallstone recurrence after medical dissolution. An overestimated threat? J Hepatol 1986; 3:241.
- Rabenstein T, Radespiel-Tröger M, Höpfner L, et al. Ten years experience with piezoelectric extracorporeal shockwave lithotripsy of gallbladder stones. Eur J Gastroenterol Hepatol 2005; 17:629.
- Sackmann M, Ippisch E, Sauerbruch T, et al. Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology 1990; 98:392.
- Villanova N, Bazzoli F, Taroni F, et al. Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment. Gastroenterology 1989; 97:726.
- Saunders KD, Cates JA, Abedin MZ, Roslyn JJ. Lovastatin and gallstone dissolution: a preliminary study. Surgery 1993; 113:28.
- Chapman BA, Burt MJ, Chisholm RJ, et al. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci 1998; 43:349.
- Kallien G, Lange K, Stange EF, Scheibner J. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology 1999; 30:14.
- Duane WC. Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid composition in healthy male subjects. J Lipid Res 1994; 35:501.
- Hoogerbrugge-vd Linden N, de Rooy FW, Jansen H, van Blankenstein M. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut 1990; 31:348.
- Tazuma S, Takizawa I, Kunita T, et al. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Metabolism 1995; 44:1410.
- Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988; 8:1147.
- Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009; 136:1593.
- Bodmer M, Brauchli YB, Krähenbühl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009; 302:2001.
- González-Pérez A, García Rodríguez LA. Gallbladder disease in the general population: association with cardiovascular morbidity and therapy. Pharmacoepidemiol Drug Saf 2007; 16:524.
- Porsch-Ozçürümez M, Hardt PD, Schnell-Kretschmer H, et al. Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur J Clin Pharmacol 2001; 56:873.
- Smith JL, Roach PD, Wittenberg LN, et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000; 15:871.
- Wilson IR, Hurrell MA, Pattinson NR, Chapman BA. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics. J Gastroenterol Hepatol 1994; 9:447.
- Erichsen R, Frøslev T, Lash TL, et al. Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am J Epidemiol 2011; 173:162.
- Smit JW, van Erpecum KJ, Renooij W, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995; 21:1523.
- Sackmann M, Koelbl R, Pauletzki J, et al. Simvastatin added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shock wave therapy. Z Gastroenterol 1995; 33:585.
- Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001; 46:540.
- Miettinen TE, Kiviluoto T, Taavitsainen M, et al. Cholesterol metabolism and serum and biliary noncholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments. Hepatology 1998; 27:649.
- Sharma BC, Agarwal DK, Baijal SS, Saraswat VA. Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol. J Clin Gastroenterol 1997; 25:433.
- Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 1998; 26:287.
- Wang HH, Portincasa P, Mendez-Sanchez N, et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008; 134:2101.
- Ramos-De la Medina A, Remes-Troche JM, Roesch-Dietlen FB, et al. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified? J Gastrointest Surg 2008; 12:2097.
- Doran J, Keighley MR, Bell GD. Rowachol--a possible treatment for cholesterol gallstones. Gut 1979; 20:312.
- Ellis WR, Somerville KW, Whitten BH, Bell GD. Pilot study of combination treatment for gall stones with medium dose chenodeoxycholic acid and a terpene preparation. Br Med J (Clin Res Ed) 1984; 289:153.
- Feretis CB, Malas EG, Mansouras AJ, et al. Endoscopic transpapillary catheterization of the gallbladder followed by external shock wave lithotripsy and solvent infusion for the treatment of gallstone disease. Gastrointest Endosc 1992; 38:19.
- Holl J, Sauerbruch T, Sackmann M, et al. Combined treatment of symptomatic gallbladder stones by extracorporeal shock-wave lithotripsy (ESWL) and instillation of methyl tert-butyl ether (MTBE). Dig Dis Sci 1991; 36:1097.
- Darzi A, Monson JR, Keeling PW, et al. Combined ultrasound-guided extracorporeal shockwave lithotripsy and MTBE instillation in the treatment of common bile duct stones. Hepatogastroenterology 1991; 38:36.
- vanSonnenberg E, Zakko S, Hofmann AF, et al. Human gallbladder morphology after gallstone dissolution with methyl tert-butyl ether. Gastroenterology 1991; 100:1718.
- Esch O, Spinosa JC, Hamilton RL, et al. Acute effects of topical methyl tert-butyl ether or ethyl propionate on gallbladder histology in animals: a comparison of two solvents for contact dissolution of cholesterol gallstones. Hepatology 1992; 16:984.
- Adam G, Knuechel R, Vorwerk D, et al. Tissue response of the biliary and digestive system of rabbits after MTBE infusion into the gallbladder. Invest Radiol 1990; 25:58.
- Thistle JL, May GR, Bender CE, et al. Dissolution of cholesterol gallbladder stones by methyl tert-butyl ether administered by percutaneous transhepatic catheter. N Engl J Med 1989; 320:633.
- Pauletzki J, Holl J, Sackmann M, et al. Gallstone recurrence after direct contact dissolution with methyl tert-butyl ether. Dig Dis Sci 1995; 40:1775.